Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.

Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF.

J Infect Dis. 2004 Dec 15;190(12):2096-103. Epub 2004 Nov 8.

PMID:
15551207
2.

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, Marshall H, Schwartz R, King J, Henderson FW, Rodriguez W, Severs JM, Wright PF, Keyserling H, Weinberg GA, Bromberg K, Loh R, Sly P, McIntyre P, Ziegler JB, Hackell J, Deatly A, Georgiu A, Paschalis M, Wu SL, Tatem JM, Murphy B, Anderson E.

J Infect Dis. 2004 Feb 1;189(3):462-70. Epub 2004 Jan 20.

PMID:
14745704
3.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.

Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, Cannon JC, Thompson J, Tsai T, Paschalis M, Wu SL, Mitcho Y, Hackell J, Murphy BR, Tatem JM.

Pediatr Infect Dis J. 2003 May;22(5):394-405.

PMID:
12792378
4.

The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.

Skiadopoulos MH, Tatem JM, Surman SR, Mitcho Y, Wu SL, Elkins WR, Murphy BR.

Vaccine. 2002 Mar 15;20(13-14):1846-52.

PMID:
11906774
5.

Direct detection of Sabin poliovirus vaccine strains in stool specimens of first-dose vaccinees by a sensitive reverse transcription-PCR method.

Buonagurio DA, Coleman JW, Patibandla SA, Prabhakar BS, Tatem JM.

J Clin Microbiol. 1999 Feb;37(2):283-9.

6.
7.
9.

Significance of a newly identified attenuating mutation in Sabin 3 oral poliovirus vaccine.

Mento SJ, Weeks-Levy C, Tatem JM, Gorgacz EJ, Waterfield WF.

Dev Biol Stand. 1993;78:93-9; discussion 99-100.

PMID:
8388835
10.

A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating.

Tatem JM, Weeks-Levy C, Georgiu A, DiMichele SJ, Gorgacz EJ, Racaniello VR, Cano FR, Mento SJ.

J Virol. 1992 May;66(5):3194-7.

11.

Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus.

Weeks-Levy C, Tatem JM, DiMichele SJ, Waterfield W, Georgiu AF, Mento SJ.

Virology. 1991 Dec;185(2):934-7. Erratum in: Virology 1992 Apr;187(2):845.

PMID:
1660210
12.

Oral poliovirus vaccine in the United States: molecular characterization of Sabin type 3 after replication in the gut of vaccinees.

Tatem JM, Weeks-Levy C, Mento SJ, DiMichele SJ, Georgiu A, Waterfield WF, Sheip B, Costalas C, Davies T, Ritchey MB, et al.

J Med Virol. 1991 Oct;35(2):101-9.

PMID:
1662701

Supplemental Content

Loading ...
Support Center